(Headache 2010; 50: 1198‐1200) One can question the clinical relevance of early
headache responses after oral and intranasal triptans. Thus, for pain‐free the early …

Background.—Rizatriptan and almotriptan are effective and well‐tolerated triptans that have
not been compared directly. Objective.—To evaluate the effectiveness of rizatriptan 10 mg …

Currently available oral triptans are not ideal, at least for 20–30% of migraine patients, due
to either response failure or adverse events. Almotriptan is a novel selective 5-HT1B/D …

A novel model-based meta-analysis was used to quantify the dose-response relationship of
sumatriptan and eletriptan for the proportion of patients that achieve migraine pain relief up …

Objective.—To reexamine the efficacy of terminating migraine headache by administration of
sumatriptan during the visual‐aura phase of the attack. Background.—Although the …

Background Almotriptan malate is a novel, selective serotonin 1B/D agonist, or triptan,
developed for the abortive treatment of migraine. In double-blind, placebo-controlled …

Almotriptan | Drugs Skip to main content SpringerLink Account Menu Find a journal Publish
with us Track your research Search Cart 1.Home 2.Drugs 3.Article Almotriptan A Review of its …

Objectives.—To compare patient‐reported use of rizatriptan 10 mg with that of almotriptan
12.5 mg per migraine attack (24 hours) in a Spanish population. Methods.—One hundred …

In a randomized, double-blind, cross-over, multicentre study, Schoenen and his colleagues
(Cephalalgia 2008; 28: 1095–105) examined whether the efficacy of triptan migraine …

Background: There is evidence that headache response rates may be higher if triptans are
used early when a migraine attack is still mild, as compared to when it is treated after pain …